ERBB2 and neoplasm: Immunohistochemical assessments for tumor subtyping concern estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) expressions, and proliferation according to the Ki-67 labeling index (Ki-67) [2,3].